Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1Cytopenia 1Bone Marrow Failure Disorders 1Anemia, Aplastic 1

Interventions

Cyclophosphamide 20Rituximab 18obinutuzumab 14Lenalidomide 14zanubrutinib 11fludarabine 10Bendamustine Hydrochloride 10Prednisone 8Magnetic Resonance Spectroscopy 8Vincristine 7Doxorubicin 7Specimen Handling 6fludarabine phosphate 5Radiotherapy 4Biopsy 4axicabtagene ciloleucel 3Whole-Body Irradiation 3tisagenlecleucel 2polatuzumab vedotin 2pirtobrutinib 2loncastuximab tesirine 2Therapeutics 2Prednisolone 2Positron Emission Tomography Computed Tomography 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Leukapheresis 2Immunotherapy, Adoptive 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Follicular × Emapalumab × Clear all
NCT06550141 2025-11-14

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Massachusetts General Hospital

Phase 2 Recruiting
28 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡